Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK and Daiichi Sankyo vaccines joint venture to become largest vaccines company in Japan
GlaxoSmithKline (GSK) today announced that it has signed an agreement with Daiichi Sankyo Co., Ltd. to form a Joint Venture (JV) which is expected to create the number one vacci...
Read more -
GlaxoSmithKline receives positive opinion in Europe from the CHMP for Nimenrix®
GSK announced that the EMA's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Nimenrix® for active...
Read more -
EU and US Regulatory Update – Tykerb/Tyverb® (lapatinib)
GlaxoSmithKline announced today that it has submitted regulatory applications in Europe and the US related to Tykerb/ Tyverb (lapatinib) and its use in combination with trastuzu...
Read more -
GSK results announcement for Q4 and full year 2011
GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders
Read more -
GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020
GSK today announced it has joined other global pharmaceutical companies and leading organisations including the WHO, the Bill & Melinda Gates Foundation, the UK Department f...
Read more -
GSK announces changes to the Board
GlaxoSmithKline plc today announced that at the company’s Annual General Meeting (AGM) in 2013, following nine years of respective service to the GSK Board, Sir Crispin Da...
Read more -
GSK responds to the recent court ruling on the COMPAS study in Mendoza, Argentina
GlaxoSmithKline respectfully disagrees with the recent court ruling in favour of the ANMAT on the fine issued to GSK regarding the administrative conduct of the COMPAS study in ...
Read more -
GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma
GSK and Theravance, Inc. today announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair™* in patients with COP...
Read more -
GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands
Agreement reached to divest brands in USA and Canada to Prestige Brands Holdings, Inc. for £426m ($660m). Process continues for divesting brands outside these markets and global...
Read more -
GSK extends pneumococcal vaccine agreement with GAVI Alliance
GSK today announced it has expanded its agreement with the GAVI Alliance in a move to help protect millions more children in the world's poorest countries from pneumococcal...
Read more -
GlaxoSmithKline and Human Genome Sciences initiate phase III trial of belimumab (Benlysta®) administered subcutaneously in subjects with systemic lupus erythematosus
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that dosing has been initiated in BLISS-SC, a new Phase III trialto evaluate the efficacy, s...
Read more -
GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium
Improvement in disease-free survival does not reach statistical significance in study of delayed adjuvant therapy with lapatinib (Tykerb or Tyverb) monotherapy in HER2 positive ...
Read more -
GSK and Help for Heroes partner to support the rehabilitation of wounded servicemen and women in the UK
GSK and Help for Heroes today announced a new partnership to help support injured British armed forces personnel successfully transition back into civilian life. The partnership...
Read more -
GSK statement in response to the Prime Minister’s speech on life sciences
"The Government’s strategy for Life Sciences is a very important next step on the journey to make the UK the best place in the world to locate pharmaceutical investme...
Read more -
Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine
GlaxoSmithKline [NYSE:GSK] today submitted additional information to the U.S. Food and Drug Administration (FDA) in support of the Biologics License Application (BLA) for the ca...
Read more -
Reporting on a core earnings basis will begin with effect from Q1 2012
Go to the Presentations and webcasts page for the full announcement.
Read more -
GSK welcomes GAVI Alliance decision to introduce vaccines against cervical cancer and rubella in the world’s poorest countries
GlaxoSmithKline today welcomed the decision of the GAVI Board to provide funding to facilitate the provision of cervical cancer immunisation programmes and rubella vaccination, ...
Read more -
GlaxoSmithKline welcomes innovative knowledge-sharing collaboration to break deadlock in antibiotic discovery and development
GlaxoSmithKline (GSK) today welcomes the European Commission’s commitment to promote collaborative research efforts to develop new antibiotics against the growing threat f...
Read more -
GSK receives initial data from the first completed phase lll study of albiglutide in type 2 diabetes
Head-to-head study primary end point did not meet non-inferiority, but results support progression towards registration
Read more -
Data published in The Lancet Oncology support high efficacy previously demonstrated by Cervarix® (HPV 16 and 18 vaccine) against precancerous cervical lesions
An analysis published today in TheLancet Oncology reinforces previous findings showing that GlaxoSmithKline's Cervarix, provided protection against advanced precancerous lesions...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
